Sugi Predict

Sugi Predict / Compounds / SCHEMBL1599348

SCHEMBL1599348

SCHEMBL1599348

Cc1cccn1S(=O)(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 7/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ RAPGEF4 Q8WZA2 3/20 0.49
▸ PPME1 Q9Y570 3/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ APEH P13798 1/20 0.47
▸ BRD4 O60885 1/20 0.44
▸ MET P08581 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ POLB P06746 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3834757 0.86 RAPGEF4 (0.65) ALDH1A1HTTRAPGEF4L3MBTL1GAA
SCHEMBL28074550 0.83 RAPGEF4 (0.49) HTR6MEN1ALDH1A1LMNATSHR
SCHEMBL11932215 0.80 RAPGEF4 (0.66) HTR6MEN1ALDH1A1LMNATSHR
SCHEMBL7063608 0.79 MAPT (0.55) MEN1ALDH1A1KMT2A
SCHEMBL10176180 0.77 HTR6 (0.47) HTR6MEN1ALDH1A1LMNAHPGD
SCHEMBL14760380 0.76 HTR6 (0.50) HTR6MEN1ALDH1A1LMNAHPGD
SCHEMBL1599343 0.76 HTR6 (0.50) HTR6MEN1ALDH1A1LMNAHPGD
SCHEMBL28139909 0.76 PPME1 (0.51) HTR6MEN1ALDH1A1LMNAHPGD
SCHEMBL28189646 0.76 HTR6 (0.50) HTR6MEN1ALDH1A1LMNAHPGD
SCHEMBL10145004 0.76 PPME1 (0.47) HTR6MEN1ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885343-A1 INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2021-09-29 — — EP disclosed
US-20170145023-A1 DIAZEPANE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-05-25 — — US disclosed
US-20170145013-A1 DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-05-25 — — US disclosed
WO-2016201370-A1 COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-15 — — WO disclosed
WO-2016073956-A1 EZH2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-05-12 — — WO disclosed
WO-2016073903-A1 USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-05-12 — — WO disclosed
WO-2016022902-A1 DIAZEPANE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-02-11 — — WO disclosed
WO-2016022970-A1 DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-02-11 — — WO disclosed
US-20150246030-A1 Compounds Having CRTH2 Antagonist Activity ATOPIX THERAPEUTICS LTD (GB) 2015-09-03 — — US disclosed
US-8980927-B2 Compounds having CRTH2 antagonist activity ATOPIX THERAPEUTICS LIMITED (GB) 2015-03-17 — — US disclosed
WO-2006021000-A2 SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON AVENTIS PHARMACEUTICALS INC. (US) 2006-02-23 — — WO disclosed
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 — — US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 — — EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 — — US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 — — US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 — — US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 — — EP disclosed
EP-0259085-B1 2-GUANIDINO-4-ARYLTHIAZOLES FOR TREATMENT OF PEPTIC ULCERS PFIZER INC. (US) 1991-08-21 — — EP disclosed
US-5026715-A 2-guanidino-4-arylthiazoles for treatment of peptic ulcers PFIZER INC. (US) 1991-06-25 — — US disclosed
EP-0259085-A1 2-Guanidino-4-arylthiazoles for treatment of peptic ulcers PFIZER INC. (US) 1988-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 HTR6 3939/4885MEN1 3581/4885ALDH1A1 476/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 HTR6 3897/4885MEN1 2979/4885ALDH1A1 603/4885
US-20150246030-A1 Compounds Having CRTH2 Antagonist Activity NR3C2, HRH2, NR2C2 HTR6 645/4885MEN1 2983/4885ALDH1A1 4087/4885
US-20170145013-A1 DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF BRDT, BRD4, BRD3 HTR6 2444/4885MEN1 2473/4885ALDH1A1 2824/4885
US-20170145023-A1 DIAZEPANE DERIVATIVES AND USES THEREOF BRDT, BRD4, BAZ2A HTR6 1822/4885MEN1 2439/4885ALDH1A1 3052/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 HTR6 3924/4885MEN1 3109/4885ALDH1A1 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.